Translesion Polymerase η Is Upregulated by Cancer Therapeutics and Confers Anticancer Drug Resistance
Published version of a preprint
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
DNA repair processes are a key determinant of the sensitivity of cancer cells to DNA-damaging chemotherapeutics, which may induce certain repair genes as a mechanism to promote resistance. Here, we report the results of a screen for repair genes induced in cancer cells treated with DNA crosslinking agents, which identified the translesion polymerase η (PolH) as a p53-regulated target acting as one defense against interstrand crosslink (ICL)-inducing agents. PolH was induced by fotemustine, mafosfamide, and lomustine in breast cancer, glioma, and melanoma cells in vitro and in vivo, with similar inductions observed in normal cells such as lymphocytes and diploid fibroblasts. PolH contributions to the protection against ICL-inducing agents were evaluated by its siRNA-mediated attenuation in cells, which elevated sensitivity to these drugs in all tumor cell models. Conversely, PolH overexpression protected cancer cells against these drugs. PolH attenuation reduced repair of ICL lesions as measured by host cell reactivation assays and enhanced persistence of γH2AX foci. Moreover, we observed a strong accumulation of PolH in the nucleus of drug-treated cells along with direct binding to damaged DNA. Taken together, our findings implicated PolH in ICL repair as a mechanism of cancer drug resistance and normal tissue protection. Cancer Res; 74(19); 5585–96. ©2014 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, this DNA polymerase was shown to be induced in several human cell lines after treatment with chemotherapeutic agents in a p53-dependent manner, and was linked to acquired resistance to chemotherapy ( 24 , 25 ).”
From Predominant role of DNA polymerase eta and p53-dependent translesion synthesis in the survival of ultraviolet-irradiated human cells (2017) · cites this paper as [24]
Citations
Cites
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
The DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705
A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050
Regulation of p53 in response to DNA damage
Lakin, N. D., & Jackson, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1203015 · Cited by 987
Kaina, B., Christmann, M., Naumann, S., & Roos, W. P. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 663
Self-citationRepair of O6-alkylguanine by alkyltransferases
Pegg, A. E. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00017-x · Cited by 576
Mechanisms of human DNA repair: an update
Christmann, M., Tomicic, M. T., Roos, W. P., & Kaina, B. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00287-7 · Cited by 576
Self-citationAvril, M. F., Aamdal, S., Grob, J. J., Hauschild, A., Mohr, P., Bonerandi, J. J., Weichenthal, M., Neuber, K., Bieber, T., Gilde, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.165 · Cited by 486
Cited by
DNA damage and the balance between survival and death in cancer biology
Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189
Self-citationLerner, L. K., Francisco, G., Soltys, D. T., Rocha, C. R. R., Quinet, A., Vessoni, A. T., Castro, L. P., David, T. I. P., Bustos, S. O., Strauss, B. E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1196 · Cited by 53
Metadata
- Authors
- Tomicic, M. T., Aasland, D., Naumann, S. C., Meise, R., Barckhausen, C., Kaina, B., & Christmann, M.
- Affiliations
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Venue
- Cancer Research
- Published
- 2014-09-30
- Volume
- 74
- Issue
- 19
- Pages
- 5585-5596
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2018187217
- Cited by
- 56
- References
- 52
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 6 · 2019: 5 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 4
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- DNA polymerase eta, interstrand crosslink repair, DNA repair, chemoresistance, p53 regulation, DNA cross-linking agents, fotemustine, mafosfamide, lomustine, host cell reactivation, γH2AX foci, normal tissue protection, breast cancer, glioma, melanoma
- MeSH terms
- Y-Family DNA Polymerases, Animals, Antineoplastic Agents, DNA-Directed DNA Polymerase, DNA Replication, Humans, Up-Regulation, Tumor Suppressor Protein p53, Mice, Inbred NOD, Drug Resistance, Neoplasm, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translesion Polymerase η Is Upregulated by Cancer Therapeutics and Confers Anticancer Drug Resistance. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-0953
- The paper
- Tomicic, M. T., Aasland, D., Naumann, S. C., Meise, R., Barckhausen, C., Kaina, B., & Christmann, M. (2014). Translesion Polymerase η Is Upregulated by Cancer Therapeutics and Confers Anticancer Drug Resistance. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-0953
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.